ClinicalTrials.gg
RecruitingNCT07361874IMPACT-MACSUpdated Nov 18, 2026

IMPACT-MACS: Adrenalectomy vs Semaglutide for Metabolic Outcomes in Mild Autonomous Cortisol Secretion

A Phase 4 interventional study of Intervention 1: Adrenalectomy and Intervention 2: Semaglutide in Mild Autonomous Cortisol Secretion (MACS), Autonomous Cortisol Secretion (ACS) and Subclinical Cushing's, sponsored by University of Texas Southwestern Medical Center. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by University of Texas Southwestern Medical Center · Phase 4, Interventional, and Treatment

How we know · 5 judgments

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.
Updated Nov 18, 2026Eligibility revisedDesign changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
75
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this study is to learn how two treatments-adrenalectomy (surgical removal of an adrenal gland) and semaglutide (a medication used for weight management)-affect insulin resistance and cortisol regulation in adults with mild autonomous cortisol secretion (MACS). The study will also learn how these treatments impact body composition, blood pressure, cholesterol, inflammation, muscle strength, and quality of life.

The main questions the study aims to answer are:

  1. Does adrenalectomy or semaglutide improve insulin resistance more in people with MACS?
  2. How do these treatments change cortisol patterns and other cardiometabolic risk factors?
  3. Do people with MACS respond differently to semaglutide compared to matched adults without MACS?
  4. Among participants who enter the optional extension phase, are treatment-related changes maintained or further modified with longer-term treatment and follow-up?

Participants will:

  1. Receive either adrenalectomy or semaglutide if they have MACS, or semaglutide if they are matched controls
  2. Complete clinic visits and phone visits
  3. Undergo metabolic testing such as blood tests, urine steroid profiling, body composition scans, blood pressure monitoring, muscle strength testing, and questionnaires about health and well-being
  4. If eligible, have the option to participate in an extension phase with continued treatment and follow-up through approximately 12 months
Read the detailed description

This single-center, prospective, interventional study evaluates metabolic responses to surgical versus medical treatment in adults with mild autonomous cortisol secretion (MACS). The study includes:

  1. a randomized controlled trial comparing adrenalectomy to semaglutide in MACS, and
  2. a parallel matched case-control comparison evaluating semaglutide effects in MACS versus matched controls without adrenal tumors.

The primary objective is to compare changes in insulin sensitivity measured by hyperinsulinemic-euglycemic clamp (M-value) from baseline to week 26. Secondary outcomes include cortisol dynamics, steroid profiling, cardiometabolic biomarkers, body composition, blood pressure, muscle strength, and patient-reported quality of life.

Semaglutide is administered within its FDA-approved indication for weight management; adrenalectomy is standard of care. No IND is required.

Participants who complete the initial 26-week study period and meet applicable eligibility criteria may elect to participate in an optional extension phase through approximately Week 52. During the extension phase, participants continue study follow-up and the intervention specified by the protocol, with additional assessments to evaluate longer-term changes in metabolic, hormonal, anthropometric, and cardiometabolic outcomes. Participation in the extension phase is voluntary and is not required for completion of the initial study period. The original primary outcome remains the change in insulin sensitivity from baseline to Week 26; assessments during the extension phase evaluate longer-term treatment effects and durability of response.

02

Conditions studied

  • Mild Autonomous Cortisol Secretion (MACS)
  • Autonomous Cortisol Secretion (ACS)
  • Subclinical Cushing's
  • Mild Autonomous Cortisol Excess

Keywords

  • Mild Autonomous Cortisol Secretion
  • MACS
  • Adrenal incidentaloma
  • Adrenal adenoma
  • Subclinical Cushing
  • Hypercortisolism
  • Cortisol dysregulation
  • Adrenalectomy
  • Semaglutide
  • Weight loss
  • Body composition
  • Insulin resistance
  • GLP-1 receptor agonist
  • Hyperinsulinemic-euglycemic clamp
  • Cortisol dynamics
  • Visceral fat
  • cardiometabolic risk
  • randomized controlled trial
03

In context

Adrenal incidentaloma

27 studies on the registry are indexed under Adrenal incidentaloma; 12 are open to participants now.

Browse Adrenal incidentaloma studies →

Lead sponsor

University of Texas Southwestern Medical Center is the lead sponsor of 1,012 studies on the registry; 200 are open to participants now.

Of its 139 completed or terminated interventional studies of FDA-regulated products, 105 (76%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

The criteria were revised on the registry on Nov 18, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults ≥18 years
  • MACS groups: adrenal adenoma + DST cortisol >1.8 µg/dL + no overt Cushing + eligible for adrenalectomy
  • Willingness to postpone surgery 6 months if randomized
  • Controls: no adrenal abnormalities + normal DST + ≥27 + ≥2 cardiometabolic conditions
  • Stable medication doses for ≥4 weeks
  • Negative pregnancy test if applicable

Exclusion criteria

Exclusion Criteria:

  • Prior GLP-1 RA within 90 days
  • Weight change >5 kg in past 90 days
  • Prior obesity/diabetes surgery
  • Type 1 diabetes or other diabetes types
  • Severe organ disease
  • Recent pancreatitis
  • Pregnancy, breastfeeding
  • to semaglutide
  • Contraindication to surgery delay
  • Chronic use

Optional Extension Phase Eligibility:

Participants who complete the Core Study Period may participate in the Optional Extension Phase if they:

  • Successfully complete all Week 26 (Visit 8) assessments and procedures;
  • Remain compliant with study requirements;
  • Are considered by the Investigator to be appropriate for safe continued participation; and
  • Confirm their willingness to participate in the Optional Extension Phase.

For matched controls, the corresponding matched index participant must also elect to participate in the Optional Extension Phase and remain eligible for continued study participation.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
75 participants (estimated)

Study arms

  • Active comparator
    Arm 1: Adrenalectomy (MACS)

    Adults with mild autonomous cortisol secretion (MACS) who are clinically eligible for adrenalectomy undergo unilateral adrenalectomy as part of standard clinical care. Participants complete protocol-specified metabolic, hormonal, cardiometabolic, body composition, physical function, and patient-reported outcome assessments through Week 26. Eligible participants may elect to participate in the Optional Extension Phase, with continued follow-up and repeat outcome assessments through Month 12.

    Procedure: Intervention 1: Adrenalectomy

  • Active comparator
    Arm 2: Semaglutide (MACS)

    Adults with MACS receive semaglutide during the initial 26-week treatment period. Eligible participants who elect to participate in the optional extension phase continue semaglutide treatment and protocol-specified follow-up through Month 12.

    Drug: Intervention 2: Semaglutide

  • Active comparator
    Arm 3: Semaglutide (Matched Controls)

    Matched adults without adrenal tumors receive semaglutide using the same dosing approach as semaglutide-treated participants with MACS. This arm allows comparison of semaglutide responses between individuals with and without MACS. Eligible matched controls may participate in the Optional Extension Phase through Month 12 if their corresponding matched index participant also elects to participate and both remain eligible for continued study participation.

    Drug: Intervention 2: Semaglutide

Interventions

  • ProcedureIntervention 1: Adrenalectomy

    Surgical removal of one adrenal gland performed by an endocrine surgeon following institutional standard-of-care practices. Includes postoperative monitoring for adrenal insufficiency and routine clinical follow-up.

  • DrugSemaglutideStudies of SemaglutideSemaglutide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Once-weekly subcutaneous semaglutide administered according to FDA-approved titration for chronic weight management (0.25 mg to 2.4 mg weekly as tolerated). Participants receive training on injection technique, dose escalation, and safety monitoring.

06

What researchers measure

Primary outcomes

  1. Change in Insulin Sensitivity (M-value), mg/kg/min

    Hyperinsulinemic-euglycemic clamp

    Time frame: Baseline to Week 26

Secondary outcomes

  1. Change in fasting plasma glucose, mg/dL

    Time frame: Baseline to Week 26; Baseline → Month 12

  2. Change in hemoglobin A1C, %

    fasting blood test

    Time frame: Baseline to Week 26; Baseline → Month 12

  3. Change in fasting insulin, µU/mL

    Fasting blood test

    Time frame: Baseline to Week 26; Baseline → Month 12

  4. Change in glucagon, pg/mL

    Fasting blood test

    Time frame: Baseline to Week 26; Baseline → Month 12

  5. Change in c-peptide, nmol/L

    Fasting blood test

    Time frame: Baseline to Week 26; Baseline → Month 12

  6. Change in IGF-1, ng/mL

    Fasting blood glucose

    Time frame: Baseline to Week 26; Baseline → Month 12

  7. Change in IGF-II, ng/mL

    Fasting blood test

    Time frame: Baseline to Week 26; Baseline → Month 12

  8. Change in IGFBP-1, ng/mL

    Fasting blood test

    Time frame: Baseline to Week 26; Baseline → Month 12

  9. Change in leptin, ng/mL

    Fasting blood glucose

    Time frame: Baseline to Week 26; Baseline → Month 12

  10. Change in adiponectin, μg/mL

    Fasting blood test

    Time frame: Baseline to Week 26; Baseline → Month 12

  11. % of patients with normal dexamethasone suppression test, %

    1-mg dexamethasone suppression test

    Time frame: Baseline to Week 26; Baseline → Month 12

  12. Change in steroid profile, ng/24h

    25-steroid profiling in the 24-hour urine, reported as aggregate

    Time frame: Baseline to Week 26; Baseline → Month 12

  13. Mean change in systolic BP, mmHg

    24-hour Ambulatory BP

    Time frame: Baseline to Week 26; Baseline → Month 12

  14. Mean change in diastolic BP, mmHg

    24-hour Ambulatory BP

    Time frame: Baseline to Week 26; Baseline → Month 12

  15. Change in cholesterol, mg/dL

    Fasting blood test

    Time frame: Baseline to Week 26; Baseline → Month 12

  16. Change in Free Fatty Acids, mmol/L

    Fasting blood test

    Time frame: Baseline to Week 26; Baseline → Month 12

  17. Change in C-reactive protein, pg/mL

    Fasting blood test

    Time frame: Baseline to Week 26; Baseline → Month 12

  18. Change in TNF-alpha, pg/mL

    Fasting blood glucose

    Time frame: Baseline to Week 26; Baseline → Month 12

  19. Change in Interleukin-1, pg/mL

    Fasting blood test

    Time frame: Baseline to Week 26; Baseline → Month 12

  20. Change in Interleukin-6, pg/mL

    Fasting blood test

    Time frame: Baseline to Week 26; Baseline → Month 12

  21. Change in body weight, kg

    electronic scale

    Time frame: Baseline to Week 26; Baseline → Month 12

  22. Change in BMI, kg/m2

    calculated from weight and height

    Time frame: Baseline to Week 26; Baseline → Month 12

  23. Change in waist circumference, cm

    Tape measure

    Time frame: Baseline to Week 26; Baseline → Month 12

  24. Change in fat area, cm2

    Limited unenhanced CT

    Time frame: Baseline to Week 26; Baseline → Month 12

  25. Change in muscle area, cm2

    Limited unenhanced CT

    Time frame: Baseline to Week 26; Baseline → Month 12

  26. Change in bone mineral density, mg/cm³

    Limited unenhanced CT

    Time frame: Baseline to Week 26; Baseline → Month 12

  27. Change in chair rise test, stands/30s

    Time test, number of stands from chair in 30 seconds

    Time frame: Baseline to Week 26; Baseline → Month 12

  28. Change in Hand Grip Strength, kg

    Dynamometer

    Time frame: Baseline to Week 26; Baseline → Month 12

  29. Change in overall quality of life, score

    PROMIS Global Health Questionnaire, domain-specific scales; The Patient-Reported Outcomes Measurement Information System (PROMIS) Global Health v1.2 Questionnaire assesses overall health-related quality of life across multiple domains, including physical health, mental health, social functioning, fatigue, and general well-being. It yields two standardized T-score summary measures (Global Physical Health and Global Mental Health). Score Range: T-scores typically range from 20 to 80. Interpretation: Higher T-scores indicate better health-related quality of life. Assessment Method: Self-report questionnaire; estimated completion time 2-5 minutes.

    Time frame: Baseline to Week 26; Baseline → Month 12

  30. Change in disease-specific QoL, score

    Cushing Quality of Life Questionnaire (CushingQoL) Description: The Cushing Quality of Life Questionnaire (CushingQoL) is a disease-specific tool assessing health-related quality of life in individuals with hypercortisolism. It contains 12 items scored on a 5-point Likert scale. Score Range: 12 (minimum) to 60 (maximum). Interpretation: Higher scores indicate better quality of life; lower scores indicate poorer quality of life. Domains: Sleep disturbances, mood, physical appearance, social interaction, health concerns. Assessment Method: Self-administered; estimated completion time \~5 minutes.

    Time frame: Baseline to Week 26; Baseline → Month 12

  31. Change in mood, score

    PROMIS Depression Short Form \& PROMIS Anxiety Short Form Description: The PROMIS Depression Short Form and PROMIS Anxiety Short Form measure depressive and anxiety symptoms over the past seven days, assessing emotional distress, negative affect, and somatic symptoms. Responses are on a 5-point Likert scale ("Never" to "Always"), converted to standardized T-scores. Score Range: T-scores typically range from 20 to 80. Interpretation: Higher scores indicate worse depressive or anxiety symptoms. Assessment Method: Self-report questionnaires; estimated completion time 2-4 minutes each.

    Time frame: Baseline to Week 26; Baseline → Month 12

  32. Change in cognition, seconds

    Trail Making Test - Part A and Part B (TMT-A and TMT-B) Description: The Trail Making Test Parts A and B assess visual attention, processing speed, cognitive flexibility, and executive function. Part A requires sequential connection of numbers; Part B requires alternating between numbers and letters. Score Range: 0 to 300 seconds (maximum test time). Interpretation: Higher (longer) completion times indicate worse cognitive performance. Assessment Method: Performance-based timed test administered by study personnel; expected duration \~5 minutes.

    Time frame: Baseline to Week 26; Baseline → Month 12

  33. Change in sleep, score

    PROMIS Sleep Disturbance Short Form Description: The PROMIS Sleep Disturbance Short Form evaluates sleep quality, difficulty initiating and maintaining sleep, and overall sleep problems over the past seven days. Scores are converted into standardized T-scores. Score Range: T-scores typically range from 20 to 80. Interpretation: Higher scores indicate worse sleep disturbance. Assessment Method: Self-administered; estimated completion time 2-4 minutes.

    Time frame: Baseline to Week 26; Baseline → Month 12

  34. Change in frailty, score

    FRAIL Scale (Fatigue, Resistance, Ambulation, Illnesses, Loss of Weight) Description: The FRAIL Scale is a validated screening instrument assessing functional decline and physiological frailty. It consists of five yes/no items: fatigue, resistance, ambulation, illnesses, and weight loss. Score Range: 0 (minimum) to 5 (maximum). Interpretation: Higher scores indicate greater frailty. Frailty Categories: 0: Robust 1-2: Pre-frail 3-5: Frail Assessment Method: Administered by study personnel; duration \~1 minute.

    Time frame: Baseline to Week 26; Baseline → Month 12

  35. Change in eating behavior, score

    Eating Behavior and Appetite Questionnaire (EBAQ) Description: The Eating Behavior and Appetite Questionnaire (EBAQ) evaluates hunger, satiety, food cravings, and changes in appetite and eating behavior. It generates domain-specific and total scores. Score Range: Varies by version; treated as continuous scores with defined minimum and maximum values per subscale. Interpretation: Higher scores indicate greater appetite or more pronounced eating-behavior disturbances. Assessment Method: Self-administered; estimated completion time 3-5 minutes.

    Time frame: Baseline to Week 26; Baseline → Month 12

  36. Adverse Events and Serious Adverse Events

    AEs, SAEs

    Time frame: From assigned intervention through 4 weeks after the end of treatment, up to approximately Month 13 for participants entering the Optional Extension Phase.

  37. Change in Insulin Sensitivity (M-value) at Month 12

    Hyperinsulinemic-euglycemic clamp

    Time frame: Time Frame: Baseline to Month 12

  38. Change in post-DST cortisol as a continuous variable

    1-mg dexamethasone suppression test

    Time frame: Baseline to Week 26; Baseline → Month 12

  39. Change in ACTH level

    Blood test

    Time frame: Baseline to Week 26; Baseline → Month 12

  40. DHEA-S

    Blood test

    Time frame: Baseline to Week 26; Baseline → Month 12

  41. HDL

    Blood test

    Time frame: Baseline to Week 26; Baseline → Month 12

  42. LDL

    Blood test

    Time frame: Baseline to Week 26; Baseline → Month 12

  43. triglycerides

    Blood test

    Time frame: Baseline to Week 26; Baseline → Month 12

  44. Apo B

    Blood test

    Time frame: Baseline to Week 26; Baseline → Month 12

  45. Lp(a)

    Blood test

    Time frame: Baseline to Week 26; Baseline → Month 12

  46. HDL function

    Blood test

    Time frame: Baseline to Week 26; Baseline → Month 12

  47. cholesterol efflux capacity

    Blood test

    Time frame: Baseline to Week 26; Baseline → Month 12

  48. Change in total fat area

    Body composition

    Time frame: Baseline to Week 26; Baseline → Month 12

  49. Change in visceral fat area

    Body composition

    Time frame: Baseline to Week 26; Baseline → Month 12

  50. Change in subcutaneous fat area

    Body composition

    Time frame: Baseline to Week 26; Baseline → Month 12

  51. Change in muscle area

    Body composition

    Time frame: Baseline to Week 26; Baseline → Month 12

  52. Change in muscle:fat ratio

    Body composition

    Time frame: Baseline to Week 26; Baseline → Month 12

  53. Change in liver fat

    Body composition

    Time frame: Baseline to Week 26; Baseline → Month 12

  54. Change in pancreatic fat

    Body composition

    Time frame: Baseline to Week 26; Baseline → Month 12

  55. Change in pancreatic volume

    Body composition

    Time frame: Baseline to Week 26; Baseline → Month 12

  56. Change in adrenal nodule size

    CT abdomen

    Time frame: Baseline to Week 26; Baseline → Month 12

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Yozamp N, Vaidya A. Assessment of mild autonomous cortisol secretion among incidentally discovered adrenal masses. Best Pract Res Clin Endocrinol Metab. 2021 Jan;35(1):101491. doi: 10.1016/j.beem.2021.101491. Epub 2021 Feb 6. PubMed 33593680 ↗
  • Bancos I, Prete A. Approach to the Patient With Adrenal Incidentaloma. J Clin Endocrinol Metab. 2021 Oct 21;106(11):3331-3353. doi: 10.1210/clinem/dgab512. PubMed 34260734 ↗
  • Prete A, Subramanian A, Bancos I, Chortis V, Tsagarakis S, Lang K, Macech M, Delivanis DA, Pupovac ID, Reimondo G, Marina LV, Deutschbein T, Balomenaki M, O'Reilly MW, Gilligan LC, Jenkinson C, Bednarczuk T, Zhang CD, Dusek T, Diamantopoulos A, Asia M, Kondracka A, Li D, Masjkur JR, Quinkler M, Ueland GA, Dennedy MC, Beuschlein F, Tabarin A, Fassnacht M, Ivovic M, Terzolo M, Kastelan D, Young WF Jr, Manolopoulos KN, Ambroziak U, Vassiliadi DA, Taylor AE, Sitch AJ, Nirantharakumar K, Arlt W; ENSAT EURINE-ACT Investigators*; ENSAT EURINE-ACT Investigators. Cardiometabolic Disease Burden and Steroid Excretion in Benign Adrenal Tumors : A Cross-Sectional Multicenter Study. Ann Intern Med. 2022 Mar;175(3):325-334. doi: 10.7326/M21-1737. Epub 2022 Jan 4. PubMed 34978855 ↗
  • Ebbehoj A, Li D, Kaur RJ, Zhang C, Singh S, Li T, Atkinson E, Achenbach S, Khosla S, Arlt W, Young WF, Rocca WA, Bancos I. Epidemiology of adrenal tumours in Olmsted County, Minnesota, USA: a population-based cohort study. Lancet Diabetes Endocrinol. 2020 Nov;8(11):894-902. doi: 10.1016/S2213-8587(20)30314-4. PubMed 33065059 ↗
  • Fassnacht M, Tsagarakis S, Terzolo M, Tabarin A, Sahdev A, Newell-Price J, Pelsma I, Marina L, Lorenz K, Bancos I, Arlt W, Dekkers OM. European Society of Endocrinology clinical practice guidelines on the management of adrenal incidentalomas, in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol. 2023 Jul 20;189(1):G1-G42. doi: 10.1093/ejendo/lvad066. PubMed 37318239 ↗
  • Kolanska K, Owecki M, Nikisch E, Sowinski J. High prevalence of obesity in patients with non-functioning adrenal incidentalomas. Neuro Endocrinol Lett. 2010;31(3):418-22. PubMed 20588242 ↗
  • Reimondo G, Castellano E, Grosso M, Priotto R, Puglisi S, Pia A, Pellegrino M, Borretta G, Terzolo M. Adrenal Incidentalomas are Tied to Increased Risk of Diabetes: Findings from a Prospective Study. J Clin Endocrinol Metab. 2020 Apr 1;105(4):dgz284. doi: 10.1210/clinem/dgz284. PubMed 31900474 ↗
  • Bovio S, Cataldi A, Reimondo G, Sperone P, Novello S, Berruti A, Borasio P, Fava C, Dogliotti L, Scagliotti GV, Angeli A, Terzolo M. Prevalence of adrenal incidentaloma in a contemporary computerized tomography series. J Endocrinol Invest. 2006 Apr;29(4):298-302. doi: 10.1007/BF03344099. PubMed 16699294 ↗

Related links

Individual participant data

Plan to share: Yes — De-identified individual participant data (IPD) from the IMPACT-MACS study will be shared in accordance with NIH Data Management and Sharing Policy. Shared IPD will include primary and secondary outcome data such as insulin sensitivity (M-value), hormonal and cardiometabolic biomarkers, body composition measures, ambulatory blood pressure data, physical function tests, patient-reported outcomes, and adverse events. No genetic data will be shared. IPD will become available at the time of primary publication or by the end of the award period, expected by Q2 2030. Data will be accessible to qualified investigators for biomedical research through the NIDDK Central Repository, with requests managed under a Data Use Agreement. IRB approval or exemption is required, and data may not be used for ancestry or non-biomedical research.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report, Analytic code

Time frame: Start Date: Individual participant data (IPD) and supporting documents will become available at the time of primary results publication or by the end of the study award period, whichever occurs first. Availability is expected to begin by Q2 2030. End Date: IPD will remain available indefinitely through the NIDDK Central Repository, as long as the repository remains active and able to distribute the data under its Data Use Agreement procedures.

Access criteria: Individual participant data (IPD) and supporting materials will be available to qualified investigators conducting health-related, medical, or biomedical research. Requestors must submit a research proposal and obtain institutional IRB approval or exemption before access is granted. Data will be shared in de-identified form through the NIDDK Central Repository, which manages requests under its governed Data Use Agreement (DUA) process. Approved investigators will be able to access the de-identified IPD, study protocol, and data dictionary through the repository's secure system. No identifiable information or genetic data will be shared.

Data sharing details ↗ · reporter.nih.gov

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2026 (actual). Primary completion is estimated for May 2030, 50 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 20, 2026
First posted
Jan 23, 2026
StartActual
Mar 5, 2026
Primary completionEst.
May 31, 2030
CompletionEst.
May 31, 2030
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Eligibility
7 exclusion criteria added
What changed in the criteria
Exclusion criteria
  • AddedOptional Extension Phase Eligibility:
  • AddedParticipants who complete the Core Study Period may participate in the Optional Extension Phase if they:
  • AddedSuccessfully complete all Week 26 (Visit 8) assessments and procedures;
  • AddedRemain compliant with study requirements;
  • AddedAre considered by the Investigator to be appropriate for safe continued participation; and
  • AddedConfirm their willingness to participate in the Optional Extension Phase.
  • AddedFor matched controls, the corresponding matched index participant must also elect to participate in the Optional Extension Phase and remain eligible for continued study participation.
Nov 18, 2026
Secondary outcomes
10 time frame changed, 20 added, 27 more
What changed in the outcomes
  • AddedChange in Insulin Sensitivity (M-value) at Month 12Time frame: Time Frame: Baseline to Month 12
  • AddedChange in post-DST cortisol as a continuous variableTime frame: Baseline to Week 26; Baseline → Month 12
  • AddedChange in ACTH levelTime frame: Baseline to Week 26; Baseline → Month 12
  • AddedDHEA-STime frame: Baseline to Week 26; Baseline → Month 12
  • AddedHDLTime frame: Baseline to Week 26; Baseline → Month 12
  • AddedLDLTime frame: Baseline to Week 26; Baseline → Month 12
  • AddedtriglyceridesTime frame: Baseline to Week 26; Baseline → Month 12
  • AddedApo BTime frame: Baseline to Week 26; Baseline → Month 12
  • AddedLp(a)Time frame: Baseline to Week 26; Baseline → Month 12
  • AddedHDL functionTime frame: Baseline to Week 26; Baseline → Month 12
  • Addedcholesterol efflux capacityTime frame: Baseline to Week 26; Baseline → Month 12
  • AddedChange in total fat areaTime frame: Baseline to Week 26; Baseline → Month 12
  • AddedChange in visceral fat areaTime frame: Baseline to Week 26; Baseline → Month 12
  • AddedChange in subcutaneous fat areaTime frame: Baseline to Week 26; Baseline → Month 12
  • AddedChange in muscle areaTime frame: Baseline to Week 26; Baseline → Month 12
  • AddedChange in muscle:fat ratioTime frame: Baseline to Week 26; Baseline → Month 12
  • AddedChange in liver fatTime frame: Baseline to Week 26; Baseline → Month 12
  • AddedChange in pancreatic fatTime frame: Baseline to Week 26; Baseline → Month 12
  • AddedChange in pancreatic volumeTime frame: Baseline to Week 26; Baseline → Month 12
  • AddedChange in adrenal nodule sizeTime frame: Baseline to Week 26; Baseline → Month 12
  • Time frameChange in fasting plasma glucose, mg/dLBaseline to Week 26 → Baseline to Week 26; Baseline → Month 12
  • Time frameChange in hemoglobin A1C, %Baseline to Week 26 → Baseline to Week 26; Baseline → Month 12
  • Time frameChange in fasting insulin, µU/mLBaseline to Week 26 → Baseline to Week 26; Baseline → Month 12
  • Time frameChange in glucagon, pg/mLBaseline to Week 26 → Baseline to Week 26; Baseline → Month 12
  • Time frameChange in c-peptide, nmol/LBaseline to Week 26 → Baseline to Week 26; Baseline → Month 12
  • Time frameChange in IGF-1, ng/mLBaseline to Week 26 → Baseline to Week 26; Baseline → Month 12
  • Time frameChange in IGF-II, ng/mLBaseline to Week 26 → Baseline to Week 26; Baseline → Month 12
  • Time frameChange in IGFBP-1, ng/mLBaseline to Week 26 → Baseline to Week 26; Baseline → Month 12
  • Time frameChange in leptin, ng/mLBaseline to Week 26 → Baseline to Week 26; Baseline → Month 12
  • Time frameChange in adiponectin, μg/mLBaseline to Week 26 → Baseline to Week 26; Baseline → Month 12
  • …and 27 more, on the record history on ClinicalTrials.gov ↗
Nov 18, 2026
Design
Not applicable→Phase 4
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    Eligibility 7 exclusion criteria added
    What changed in the criteria
    Exclusion criteria
    • AddedOptional Extension Phase Eligibility:
    • AddedParticipants who complete the Core Study Period may participate in the Optional Extension Phase if they:
    • AddedSuccessfully complete all Week 26 (Visit 8) assessments and procedures;
    • AddedRemain compliant with study requirements;
    • AddedAre considered by the Investigator to be appropriate for safe continued participation; and
    • AddedConfirm their willingness to participate in the Optional Extension Phase.
    • AddedFor matched controls, the corresponding matched index participant must also elect to participate in the Optional Extension Phase and remain eligible for continued study participation.
    Secondary outcomes 10 time frame changed, 20 added, 27 more
    What changed in the outcomes
    • AddedChange in Insulin Sensitivity (M-value) at Month 12Time frame: Time Frame: Baseline to Month 12
    • AddedChange in post-DST cortisol as a continuous variableTime frame: Baseline to Week 26; Baseline → Month 12
    • AddedChange in ACTH levelTime frame: Baseline to Week 26; Baseline → Month 12
    • AddedDHEA-STime frame: Baseline to Week 26; Baseline → Month 12
    • AddedHDLTime frame: Baseline to Week 26; Baseline → Month 12
    • AddedLDLTime frame: Baseline to Week 26; Baseline → Month 12
    • AddedtriglyceridesTime frame: Baseline to Week 26; Baseline → Month 12
    • AddedApo BTime frame: Baseline to Week 26; Baseline → Month 12
    • AddedLp(a)Time frame: Baseline to Week 26; Baseline → Month 12
    • AddedHDL functionTime frame: Baseline to Week 26; Baseline → Month 12
    • Addedcholesterol efflux capacityTime frame: Baseline to Week 26; Baseline → Month 12
    • AddedChange in total fat areaTime frame: Baseline to Week 26; Baseline → Month 12
    • AddedChange in visceral fat areaTime frame: Baseline to Week 26; Baseline → Month 12
    • AddedChange in subcutaneous fat areaTime frame: Baseline to Week 26; Baseline → Month 12
    • AddedChange in muscle areaTime frame: Baseline to Week 26; Baseline → Month 12
    • AddedChange in muscle:fat ratioTime frame: Baseline to Week 26; Baseline → Month 12
    • AddedChange in liver fatTime frame: Baseline to Week 26; Baseline → Month 12
    • AddedChange in pancreatic fatTime frame: Baseline to Week 26; Baseline → Month 12
    • AddedChange in pancreatic volumeTime frame: Baseline to Week 26; Baseline → Month 12
    • AddedChange in adrenal nodule sizeTime frame: Baseline to Week 26; Baseline → Month 12
    • Time frameChange in fasting plasma glucose, mg/dLBaseline to Week 26 → Baseline to Week 26; Baseline → Month 12
    • Time frameChange in hemoglobin A1C, %Baseline to Week 26 → Baseline to Week 26; Baseline → Month 12
    • Time frameChange in fasting insulin, µU/mLBaseline to Week 26 → Baseline to Week 26; Baseline → Month 12
    • Time frameChange in glucagon, pg/mLBaseline to Week 26 → Baseline to Week 26; Baseline → Month 12
    • Time frameChange in c-peptide, nmol/LBaseline to Week 26 → Baseline to Week 26; Baseline → Month 12
    • Time frameChange in IGF-1, ng/mLBaseline to Week 26 → Baseline to Week 26; Baseline → Month 12
    • Time frameChange in IGF-II, ng/mLBaseline to Week 26 → Baseline to Week 26; Baseline → Month 12
    • Time frameChange in IGFBP-1, ng/mLBaseline to Week 26 → Baseline to Week 26; Baseline → Month 12
    • Time frameChange in leptin, ng/mLBaseline to Week 26 → Baseline to Week 26; Baseline → Month 12
    • Time frameChange in adiponectin, μg/mLBaseline to Week 26 → Baseline to Week 26; Baseline → Month 12
    • …and 27 more, on the record history on ClinicalTrials.gov ↗
    Design Not applicable→Phase 4
    + 4 other changes: verification date, oversight details, description and arm descriptions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07361874
Responsible party
Oksana Hamidi, DO, MSCS (Associate Professor, University of Texas Southwestern Medical Center) — Principal investigator
First posted
Jan 23, 2026
Start date
Mar 5, 2026
Primary completion
May 31, 2030 (estimated)
Completion
May 31, 2030 (estimated)
Last update
Nov 18, 2026

Study contacts

Oksana Hamidi, DO, MSCS
Contact
oksana.hamidi@utsouthwestern.edu
214-645-6397

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Semaglutide

Start the discussion